Call for Speaker Proposals
第1屆
Emerging Targeted Oncology Partnering Forum
-為了在癌治療領域合作的論壇-
2月19日∼20日
在特定的患者集體中，加深對促進癌進行分子機制的理解，已從以非特定多數人作為對象之診斷法和治療法為主流的時代，急劇變化成重視個別化、縮小標的方法的時代。最近導入縮小利用低分子治療藥和高分子治療藥標的的治療。然進行這種治療時，要執行引進診斷（companion），判斷哪個患者要實施什麼樣的治療才是最適合的情況占大半。此外，可標的化的機制數亦增加。然大半因應這種標的的方法，才處於剛開始開發的階段。此時期，剛加入開發新方法不久的企業，以及能從技術、遵守法規、促進銷售等面支援新治療法和診斷法開發的有力企業，建立合作關係就變得極為重要。此論壇的目的在於將正在開發癌新治療法和診斷法的新興企業、為尋求能實現個別化癌治療方法新能力的製藥公司、生物科技企業及診斷技術的企業連結起來。
Preliminary Program Advisory Board:
Dr. John Meduri, Strategic Planning & Business Development, BD Diagnostics
Dr. Andrea Lauber, Head, Transactions for Clinical Biomarkers & Pharmacodiagnostics Strategy, Alliances & Transactions, Bristol Myers Squibb
Dr. Rosanne Welcher, Vice President, Research & Development, DAKO
Mollie Roth, Chief Operating Officer, Diaceutics
Dr. Premal Shah, Director, Business Development, Genomic Health
Dr. Eric Lai, Senior Vice President, Research & Development, Gen-Probe
Dr. Steven Anderson, Chief Scientific Officer & Vice President, LabCorp
Dr. Jorge Leon, President, Leomics Consulting
Alan Carter, President, MDX Consulting
Dr. Brian DeChairo, Senior Director & Development Head, Medco Health Solutions
Dr. Thomas Li , Senior Director, Technology Management, Roche Diagnostics
Brian Atwood, Managing Director, Versant Ventures
Featured approaches will include, but are not limited to:
- Small Molecule Therapeutics
- Targeting Kinases
- Targeting HDAC
- Targeting VEGF and Angiogenic Factors
- Cancer Vaccines
- Monoclonal Antibody Therapeutics
- Targeting of Cancer Stem Cells
- Targeting of Cancer Cell Metabolism
- Other Novel Targeted Therapeutics
- Companion Diagnostics
- Cancer Biomarkers
